Primary Open Angle Glaucoma (POAG) Clinical Trial
Official title:
A Randomized, Multi-site, Double-masked Study Evaluating the Safety and Tolerability of QLS-111 vs Vehicle in Primary Open-angle Glaucoma or Ocular Hypertension Patients
Verified date | August 2023 |
Source | Qlaris Bio, Inc. |
Contact | Lisa Brandano |
Phone | 9789302103 |
lbrandano[@]qlaris.bio | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 5, 2024 |
Est. primary completion date | September 5, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - Able to provide written acknowledgement of giving informed consent - Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) =24 mmHg, in either eye - Post-washout IOP =22 mmHg in morning on Visits 2 and 3 and =18 mmHg at noon on Visit 2 Exclusion Criteria: - IOP >34 mmHg - Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications - Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study) - Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye - Use of other ophthalmic concomitant medications during the study - Uncontrolled hypertension or hypotension - Significant systemic or psychiatric disease - Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product - Pregnant or lactating |
Country | Name | City | State |
---|---|---|---|
United States | Coastal Research Associates, LLC | Roswell | Georgia |
Lead Sponsor | Collaborator |
---|---|
Qlaris Bio, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs) | Ocular safety and tolerability: adverse events (AEs) | 21 days | |
Primary | Clinically significant change in visual acuity | Ocular safety and tolerability: visual acuity | 21 days | |
Primary | Clinically significant change in findings on slit lamp exam | Ocular safety and tolerability: slit lamp | 21 days | |
Primary | Clinically significant change in findings on fundus exam | Ocular safety and tolerability: fundus | 21 days | |
Primary | Incidence of systemic TEAEs | Systemic safety and tolerability: AEs | 21 days | |
Primary | Clinically significant changes in blood pressure (BP) | Systemic safety and tolerability: vital signs | 21 days | |
Primary | Clinically significant changes in heart rate (HR) | Systemic safety and tolerability: vital signs | 21 days | |
Secondary | Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye | Ocular hypotensive efficacy: diurnal IOP CFB | 21 days | |
Secondary | CFB in IOP at various timepoints in the study eye | Ocular hypotensive efficacy: CFB for multiple timepoints throughout day | up to 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01085357 -
Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery
|
N/A | |
Completed |
NCT02434692 -
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
|
N/A | |
Completed |
NCT02700984 -
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
|
N/A | |
Completed |
NCT01517477 -
One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
|
N/A | |
Terminated |
NCT01180062 -
Safety Study of Latanoprost Slow Release Insert
|
Phase 1 | |
Terminated |
NCT03478293 -
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
|
N/A | |
Completed |
NCT01166659 -
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
|
N/A | |
Completed |
NCT01252849 -
Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
|
N/A | |
Active, not recruiting |
NCT00902109 -
Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients
|
N/A |